Silence Therapeutics — Second Quarter 2026 Earnings Summary

Financial Performance

• Cash and cash equivalents totaled $72.1 million as of June 30, 2026, compared to $11.3 million at December 31, 2025.
• Revenue for the three months ended June 30, 2026, was $0, compared to $224,000 in the same period of 2025.
• Research and development (R&D) expenses were $9.1 million for the three months ended June 30, 2026, a decrease from $17.6 million in the prior year period, driven by the completion of zerlasiran Phase 3 readiness and reduced personnel costs.
• General and administrative (G&A) expenses were $4.7 million for the three months ended June 30, 2026, down from $5.1 million in the prior year period.
• Net loss was $12.3 million ($0.09 per share) for the three months ended June 30, 2026, compared to a net loss of $27.4 million ($0.19 per share) in the prior year period.
• Total outstanding shares were 141,739,180 as of June 30, 2026.
• Total assets were $106.4 million as of June 30, 2026, down from $131.4 million at December 31, 2025.
• Total shareholders' equity was negative $38.5 million as of June 30, 2026, compared to negative $62.3 million at December 31, 2025.

Business Segments and Product Lines

• Divesiran (siRNA silencing TMPRSS6): Follow-up data from the Phase 1 SANRECO trial presented at the EHA 2026 Annual Congress demonstrated durable efficacy and a potential best-in-class profile for polycythemia vera (PV). Patient dosing was completed in the Phase 2 SANRECO double-blind, placebo-controlled trial evaluating 6 mg/kg doses (Q6W and Q12W) in 48 phlebotomy-dependent PV patients.
• SLN312 (AZD1705): Phase 1 results from the AstraZeneca collaboration presented at the EAS 2026 Congress showed a favorable safety profile and dose-dependent, durable reductions in ANGPTL3 protein levels and atherogenic lipoproteins (LDL-C, Apo-B, non-HDL-C).
• Pre-clinical Pipeline: SLN365 (GPR146) data confirmed lipid effects were not altered by co-treatment with statins or ezetimibe, positioning the program for a potential IND filing in 2027. SLN098 (INHBE) data in a diet-induced obesity mouse model showed reduced visceral fat and preserved lean body mass, also positioning the program for a potential IND filing in 2027.
• Preclinical Publication: An American Journal of Hematology publication detailed preclinical data on TMPRSS6 silencing as a therapeutic approach for myelodysplastic syndrome (MDS).

Other Key Points

• The company is advancing a pipeline of siRNA product candidates targeting rare and common diseases using its mRNAi GOLD platform.
• The press release includes a standard "Forward-Looking Statements" disclaimer noting risks related to clinical development timelines, regulatory approval, capital requirements, and intellectual property.
• Contact for investor inquiries is Gem Hopkins, VP, Head of IR and Corporate Communications.